SRGN and breast cancer: In the present PyMT+ mammary tumour mouse model SG+/- and SG-/- PyMT+ mice had similar numbers and weight of primary mammary tumours, expressed comparable levels of CD31 and displayed equal fibrinogen leakage, suggesting that genetic ablation of serglycin not affected the overall primary tumour growth or vessel formation.